These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 25518257

  • 1. Grey matter atrophy in patients suffering from multiple sclerosis.
    Kincses ZT, Tóth E, Bankó N, Veréb D, Szabó N, Csete G, Faragó P, Király A, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Sep 30; 67(9-10):293-300. PubMed ID: 25518257
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.
    Stüve O, Hemmer B.
    Mult Scler; 2012 Nov 30; 18(11):1514-6. PubMed ID: 23100520
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Exploring the origins of grey matter damage in multiple sclerosis.
    Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJ, Reynolds R, Martin R.
    Nat Rev Neurosci; 2015 Mar 30; 16(3):147-58. PubMed ID: 25697158
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [2012: Update on diagnosis and treatment of multiple sclerosis].
    Havla J, Kümpfel T, Hohlfeld R.
    Dtsch Med Wochenschr; 2012 Apr 30; 137(17):894-9. PubMed ID: 22492476
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
    Fox RJ.
    Mult Scler; 2013 Jan 30; 19(1):24-5. PubMed ID: 23303880
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.